Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections

被引:76
|
作者
Andeweg, Stijn P. [1 ]
de Gier, Brechje [1 ]
Eggink, Dirk [1 ]
van den Ende, Caroline [1 ]
van Maarseveen, Noortje [2 ,3 ]
Ali, Lubna [2 ]
Vlaemynck, Boris [4 ]
Schepers, Raf [4 ]
Hahne, Susan J. M. [1 ]
Reusken, Chantal B. E. M. [1 ]
de Melker, Hester E. [1 ]
van den Hof, Susan [1 ]
Knol, Mirjam J. [1 ]
机构
[1] Ctr Infect Dis Control, Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands
[2] Saltro Diagnost Ctr Primary Care, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands
[4] SYNLAB, Heppignies, Belgium
关键词
D O I
10.1038/s41467-022-31838-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The protection of COVID-19 vaccines against emerging variants needs to be monitored. Here, the authors use community testing data from the Netherlands and find that protection against infection by Omicron subvariants BA.1 and 2 is low and that booster vaccines considerably but temporarily increase protection. Given the emergence of the SARS-CoV-2 Omicron BA.1 and BA.2 variants and the roll-out of booster COVID-19 vaccination, evidence is needed on protection conferred by primary vaccination, booster vaccination and previous SARS-CoV-2 infection by variant. We employed a test-negative design on S-gene target failure data from community PCR testing in the Netherlands from 22 November 2021 to 31 March 2022 (n = 671,763). Previous infection, primary vaccination or both protected well against Delta infection. Protection against Omicron BA.1 infection was much lower compared to Delta. Protection was similar against Omicron BA.1 compared to BA.2 infection after previous infection, primary and booster vaccination. Higher protection was observed against all variants in individuals with both vaccination and previous infection compared with either one. Protection against all variants decreased over time since last vaccination or infection. We found that primary vaccination with current COVID-19 vaccines and previous SARS-CoV-2 infections offered low protection against Omicron BA.1 and BA.2 infection. Booster vaccination considerably increased protection against Omicron infection, but decreased rapidly after vaccination.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
    Vasin, Andrey V.
    Stukova, Marina A.
    LANCET INFECTIOUS DISEASES, 2023, 23 (08): : 880 - 881
  • [22] In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
    Franck Touret
    Cécile Baronti
    Boris Pastorino
    Paola Mariela Saba Villarroel
    Laetitia Ninove
    Antoine Nougairède
    Xavier de Lamballerie
    Scientific Reports, 12
  • [23] In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
    Touret, Franck
    Baronti, Cecile
    Pastorino, Boris
    Villarroel, Paola Mariela Saba
    Ninove, Laetitia
    Nougairede, Antoine
    de Lamballerie, Xavier
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [24] Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
    Fang, Zhenhao
    Peng, Lei
    Lucas, Carolina
    Lin, Qianqian
    Zhou, Liqun
    Yang, Luojia
    Feng, Yanzhi
    Ren, Ping
    Renauer, Paul A.
    Monteiro, Valter S.
    Hahn, Anne M.
    Park, Jonathan J.
    Zhou, Xiaoyu
    Grubaugh, Nathan D.
    Wilen, Craig B.
    Chen, Sidi
    CELL DISCOVERY, 2022, 8 (01)
  • [25] Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
    Zhenhao Fang
    Lei Peng
    Carolina Lucas
    Qianqian Lin
    Liqun Zhou
    Luojia Yang
    Yanzhi Feng
    Ping Ren
    Paul A. Renauer
    Valter S. Monteiro
    Anne M. Hahn
    Jonathan J. Park
    Xiaoyu Zhou
    Nathan D. Grubaugh
    Craig B. Wilen
    Sidi Chen
    Cell Discovery, 8
  • [26] SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2
    de Michelena, Paula
    Olea, Beatriz
    Torres, Ignacio
    Gonzalez-Candelas, Fernando
    Navarro, David
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (12) : 5836 - 5840
  • [27] Comparison of SARS-CoV-2 aerosol emission from patients with Omicron BA.1 or BA.2 subvariant infection
    Zhang, Yidun
    Li, Jiaming
    Jiang, Lina
    Chen, Qi
    Fu, Yingying
    Jin, Yifei
    Chen, Zehui
    Tang, Fei
    Zeng, Xiaohong
    Wen, Huixin
    Lu, Bing
    Li, Li
    Zheng, Jing
    Wang, Zhongyi
    JOURNAL OF INFECTION, 2022, 85 (02) : E37 - E39
  • [28] Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
    Mykytyn, Anna Z.
    Rissmann, Melanie
    Kok, Adinda
    Rosu, Miruna E.
    Schipper, Debby
    Breugem, Tim, I
    van den Doel, Petra B.
    Chandler, Felicity
    Bestebroer, Theo
    de Wit, Maurice
    van Royen, Martin E.
    Molenkamp, Richard
    Munnink, Bas B. Oude
    de Vries, Rory D.
    GeurtsvanKessel, Corine
    Smith, Derek J.
    Koopmans, Marion P. G.
    Rockx, Barry
    Lamers, Mart M.
    Fouchier, Ron A. M.
    Haagmans, Bart L.
    SCIENCE IMMUNOLOGY, 2022, 7 (75)
  • [29] Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection
    Perez-Saez, Javier
    Zaballa, Maria-Eugenia
    Lamour, Julien
    Yerly, Sabine
    Dubos, Richard
    Courvoisier, Delphine
    Villers, Jennifer
    Balavoine, Jean-Francois
    Pittet, Didier
    Kherad, Omar
    Vuilleumier, Nicolas
    Kaiser, Laurent
    Guessous, Idris
    Stringhini, Silvia
    Azman, Andrew
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [30] Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus
    Richter, Jan
    Koptides, Dana
    Tryfonos, Christina
    Alexandrou, Denise
    Christodoulou, Christina
    MICROORGANISMS, 2022, 10 (09)